ArticleMedicine2026
Prediction of axillary lymph node metastasis in breast cancer using preoperative CT Hounsfield units: A retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preoperative evaluation of axillary lymph node metastasis is crucial for selecting the optimal perioperative treatment for breast cancer. The most common methods for this evaluation include imaging tests, such as ultrasonography, and pathological assessments. This study investigated the utility of computed tomography (CT) Hounsfield units (HU) in diagnosing axillary lymph node metastasis. This retrospective study examined 218 patients with breast cancer who underwent surgery at our hospital between June 2017 and December 2023. We measured the HU of axillary lymph nodes using preoperative CT scans and defined the highest value as CT-HUmax. We explored the relationship between axillary lymph node CT-HUmax and the presence of metastasis. There were 56 patients in the axillary lymph node metastasis-positive group (P group) and 162 in the axillary lymph node metastasis-negative group (N group). The median CT-HUmax value was 48 (-25-69) for the P group and 30 (-17-73) for the N group, with the former having significantly higher values than those of the latter (P < .001). Similar findings were obtained with contrast-enhanced CT (CE-CT). Multivariate analysis revealed that CT-HUmax was a predictive factor for metastasis (odds ratio [OR]: 1.035; 95% confidence interval [CI]: 1.019-1.072; P = .011). The area under the receiver operating characteristic curve for CT-HUmax was 0.761 (95% CI: 0.688-0.834, P < .001). The cutoff value for CT-HUmax was 46, while the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy rate using this value were 61%, 84%, 57%, 86%, and 78%, respectively. When CE-CT was used, the cutoff value was 134, and accuracy was 79%. CT-HU may be an effective predictor of axillary lymph node metastasis in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.